Incretin mimetics as a novel therapeutic option for hepatic steatosis

@article{Tushuizen2006IncretinMA,
  title={Incretin mimetics as a novel therapeutic option for hepatic steatosis},
  author={M. Tushuizen and M. Bunck and P. Pouwels and J. V. van Waesberghe and M. Diamant and R. Heine},
  journal={Liver International},
  year={2006},
  volume={26}
}
Abstract: Background: Fat accumulation in the liver or non‐alcoholic fatty liver disease (NAFLD) is regarded as a key pathogenic factor and component of the metabolic syndrome. It was reported that administration of the incretin mimetic exenatide reversed hepatic steatosis in an obese mouse model. We had the opportunity to study the effect of additional exenatide administration on liver fat content in a patient with type 2 diabetes. 
129 Citations
GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
Potential of incretin-based therapies for non-alcoholic fatty liver disease.
Management of Nonalcoholic Fatty Liver Disease (NAFLD)
Chapter 6 Management of Nonalcoholic Fatty Liver Disease ( NAFLD )
Review: Treatment options for nonalcoholic fatty liver disease
  • S. Chitturi
  • Medicine
  • Therapeutic advances in gastroenterology
  • 2008
Review of treatment options for nonalcoholic fatty liver disease.
...
1
2
3
4
5
...

References

SHOWING 1-9 OF 9 REFERENCES
Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models.
Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.
Quantification of liver fat using magnetic resonance spectroscopy.
Estimation of metabolite concentrations from localized in vivo proton NMR spectra
  • S. Provencher
  • Chemistry, Medicine
  • Magnetic resonance in medicine
  • 1993